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model resources use. A reliable clinical and primary cost-
effectiveness study is warranted to take into account Canadian
publicly-funded health care system.
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OBJECTIVE: Epilepsy represents a national health problem. In
Mexico there are between 1.2 and 2.2 million diagnosed patients
who raise the demand for health care services. The aim of this
study was to analyze which antiepileptic drug is a cost-effective
therapy as an adjuvant treatment for the management of refrac-
tory partial seizures using a health care payer’s perspective.
\METHODS: A three-stage Markov model was used with a
follow-up period of one-year (4 cycles). Effectiveness measures
were the percentage of patients under control (no seizures) and
the number of hospitalizations avoided. The transition probabili-
ties were obtained from national and international published
literature. Comparators used in the assessment were topira-
mate (300–800 mg/day), levetiracetam (2000–3000 mg/day),
gabapentin (1200–1800 mg/day), lamotrigine (75–400 mg/day),
vigabatrin (1000–3000 mg/day) and pregabalin (150–600 mg/
day). Estimation of resource use was performed employing
hospital records from hospitals of the Social Security Mexican
Institute (IMSS). They include days of hospitalization, emer-
gency, outpatient services and drugs costs. The model was cali-
brated and probabilistic sensitivity analyses were conducted
using bootstrapping techniques. RESULTS: The highest rate of
controlled-patients was for pregabalin (54.1%;CI95% 53.3%–
55.1%) followed by topiramate (42.2%;CI95%41.5%–43.1%);
levetiracetam (34.1%;CI95% 33.4%–34.8%); vigabatrin
(32.6%;CI95% 32.0%–33.4%); gabapentin (27.4%;CI95%
26.9%–28.1%) and lamotrigine (24.7%;CI95% 24.1%–
25.3%). The annual expected mean cost per patient resulted
in US$3136.4 (CI95% US$3076.2–US$3139.8) for pregabalin;
US$4295.9 (CI95% US$4269.8–US$4318.3) for topiramate;
US$4037.7 (CI95% US$4015.6–US$4059.8) for levetirace-
tam; US$3470.9 (CI95% US$3450.1–US$3493.3) for
vigabatrin; US$3581.6 (CI95% US$3,552.3–US$3615.8) for
gabapentin; and US$2807.2 (CI95% US$2789.1–US$2825.4)
for lamotrigine. The ICER’s of the alternatives choosing
gabapentin as the gold standard were -US$1,769 (CI95%,
-US$1,685.3–US$1,812.8) for pregabalin, US$4,826.5 (CI95%
US$4,143.7–US$4,895.8) for topiramate; US$6,807.9 (CI95%
US$5,821.4–US$6986.7) for levetiracetam; -US$2,127.9
(CI95% -US$2,381.8,-US$1,561.2) for vigabatrin and
US$28,681.6 (CI95% US$28,569.1–US$49,547.0) for lamot-
rigine. Acceptability curves and component analyses showed that
these results remain robust. CONCLUSION: Pregabalin demon-
strated to be a cost-saving and cost-effectiveness adjuvant
therapy in the management of refractory partial seizures in
Mexican patients.
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OBJECTIVE: Natalizumab is a new disease modifying therapy
currently licensed for use in patients with relapsing-remitting
multiple sclerosis (RRMS), and has recently been the subject of a
cost-effectiveness evaluation by the National Institute for Health
and Clinical Excellence (NICE) in the UK. NICE accepted that
natalizumab was cost-effective in a highly-active subgroup of
RRMS patients, but not in all patients failing on current therapy
(sub-optimal therapy, SOT patients). In the SOT patients, the
basecase ICERs exceeded £43,400 and NICE essentially con-
cluded that natalizumab would not be a cost-effective use of NHS
resources in these patients unless they were having two or more
relapses per year. However, NICE recognised that the evaluation
may have underestimated the incremental QALY in two areas.
The ﬁrst was that the relapse disutility was underestimated, and
the second was that the time horizon of the evaluation was too
short. Here we re-evaluated the ICERs for natalizumab vs.
interferon-beta and glatiramer acetate in SOT patients taking
into account the points raised by NICE. METHODS: The origi-
nal model submitted to NICE was a 20-year markov-model
parameterised for the UK from a direct health care perspective.
Disutilities for relapse were updated using values from a previous
UK Health Technology Assessment, and the cost of relapse was
changed in line with contemporary studies. The time-horizon for
the model was extended from 20 years to 30 years. RESULTS:
The ICER from a direct medical costs perspective for natali-
zumab vs. interferon-beta was £29,900 per QALY. For natali-
zumab vs. glatiramer acetate the ICER was £29,300 per QALY.
CONCLUSION: The European Medicines Evaluation Agency
has approved natalizumab for use in highly active RRMS, includ-
ing SOT patients. Given the willingness-to-pay threshold of
£30,000 per QALY commonly associated with NICE guidance,
the results here show that natalizumab is a cost-effective treat-
ment for all patients failing on current therapy in the UK.
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OBJECTIVE: To determine the incremental cost-utility ratio
(ICUR) of Sativex®, a novel, cannabis-based therapy, as ad-
junctive treatment for neuropathic pain in MS adults from a
Canadian provincial government payer perspective over a one-
year time horizon. METHODS: Efﬁcacy and safety of Sativex®
were extracted from the pivotal phase III trial comparing
Sativex®+standard analgesic care (SAC) to SAC alone. Direct
medical resources (medication, health professionals, lab and
diagnostic) were taken from a burden of illness study. Sativex®
utilization for the economic analysis was based on the utilization
in the pivotal study (# sprays per day). Costs (2006 CND$) were
based on provincial sources. Utilities were based on a mapping
exercise whereby pain severity (BS-11) from the pivotal trial was
mapped onto Health Utilities Index Mark 3 (HUI) pain attribute
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